Revance therapeutics, inc. being investigated on behalf of revance therapeutics, inc. investors. contact levi & korsinsky for details.

New york, ny / accesswire / november 4, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of revance therapeutics, inc. ("revance therapeutics, inc.") (nasdaq:rvnc) concerning possible violations of federal securities laws. on september 23, 2024, revance disclosed in a filing with the u.s. securities and exchange commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell teoxane products, under the company's exclusive distribution agreement with teoxane sa".
RVNC Ratings Summary
RVNC Quant Ranking